Literature DB >> 33617938

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.

V Subbiah1, T Shen2, M Tetzlaff3, A Weissferdt3, L A Byers4, T Cascone4, A Behrang5, F Meric-Bernstam6, B H M Mooers7, S M Rothenberg8, K Ebata9, J Wu10.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33617938      PMCID: PMC8119360          DOI: 10.1016/j.annonc.2021.02.010

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   51.769


× No keyword cloud information.
  5 in total

1.  Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

Authors:  Alexander Drilon; Geoffrey R Oxnard; Daniel S W Tan; Herbert H F Loong; Melissa Johnson; Justin Gainor; Caroline E McCoach; Oliver Gautschi; Benjamin Besse; Byoung C Cho; Nir Peled; Jared Weiss; Yu-Jung Kim; Yuichiro Ohe; Makoto Nishio; Keunchil Park; Jyoti Patel; Takashi Seto; Tomohiro Sakamoto; Ezra Rosen; Manisha H Shah; Fabrice Barlesi; Philippe A Cassier; Lyudmila Bazhenova; Filippo De Braud; Elena Garralda; Vamsidhar Velcheti; Miyako Satouchi; Kadoaki Ohashi; Nathan A Pennell; Karen L Reckamp; Grace K Dy; Jürgen Wolf; Benjamin Solomon; Gerald Falchook; Kevin Ebata; Michele Nguyen; Binoj Nair; Edward Y Zhu; Luxi Yang; Xin Huang; Elizabeth Olek; S Michael Rothenberg; Koichi Goto; Vivek Subbiah
Journal:  N Engl J Med       Date:  2020-08-27       Impact factor: 91.245

2.  RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.

Authors:  Benjamin J Solomon; Lavinia Tan; Jessica J Lin; Stephen Q Wong; Sebastian Hollizeck; Kevin Ebata; Brian B Tuch; Satoshi Yoda; Justin F Gainor; Lecia V Sequist; Geoffrey R Oxnard; Oliver Gautschi; Alexander Drilon; Vivek Subbiah; Christine Khoo; Edward Y Zhu; Michele Nguyen; Dahlia Henry; Kevin R Condroski; Gabrielle R Kolakowski; Eliana Gomez; Joshua Ballard; Andrew T Metcalf; James F Blake; Sarah-Jane Dawson; Wayne Blosser; Louis F Stancato; Barbara J Brandhuber; Steve Andrews; Bruce G Robinson; S Michael Rothenberg
Journal:  J Thorac Oncol       Date:  2020-01-24       Impact factor: 15.609

3.  Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.

Authors:  V Subbiah; T Shen; S S Terzyan; X Liu; X Hu; K P Patel; M Hu; M Cabanillas; A Behrang; F Meric-Bernstam; P T T Vo; B H M Mooers; J Wu
Journal:  Ann Oncol       Date:  2020-11-05       Impact factor: 32.976

4.  Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.

Authors:  Ezra Y Rosen; Melissa L Johnson; Alexander Drilon; Geoffrey R Oxnard; Sarah E Clifford; Romel Somwar; Jennifer F Kherani; Jieun Son; Arrien A Bertram; Monika A Davare; Eric Gladstone; Elena V Ivanova; Dahlia N Henry; Elaine M Kelley; Mika Lin; Marina S D Milan; Binoj C Nair; Elizabeth A Olek; Jenna E Scanlon; Morana Vojnic; Kevin Ebata; Jaclyn F Hechtman; Bob T Li; Lynette M Sholl; Barry S Taylor; Marc Ladanyi; Pasi A Jänne; S Michael Rothenberg
Journal:  Clin Cancer Res       Date:  2020-10-20       Impact factor: 13.801

5.  Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.

Authors:  J J Lin; S V Liu; C E McCoach; V W Zhu; A C Tan; S Yoda; J Peterson; A Do; K Prutisto-Chang; I Dagogo-Jack; L V Sequist; L J Wirth; J K Lennerz; A N Hata; M Mino-Kenudson; V Nardi; S-H I Ou; D S-W Tan; J F Gainor
Journal:  Ann Oncol       Date:  2020-09-29       Impact factor: 51.769

  5 in total
  6 in total

Review 1.  Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.

Authors:  Jacob J Adashek; Aakash P Desai; Alexander Y Andreev-Drakhlin; Jason Roszik; Gilbert J Cote; Vivek Subbiah
Journal:  Mol Cancer Ther       Date:  2021-09-06       Impact factor: 6.261

Review 2.  Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.

Authors:  Antonio Matrone; Carla Gambale; Alessandro Prete; Rossella Elisei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 6.055

Review 3.  Precision therapy for RET-altered cancers with RET inhibitors.

Authors:  Kyaw Z Thein; Vamsidhar Velcheti; Blaine H M Mooers; Jie Wu; Vivek Subbiah
Journal:  Trends Cancer       Date:  2021-08-12

Review 4.  RET signaling pathway and RET inhibitors in human cancer.

Authors:  Angelina T Regua; Mariana Najjar; Hui-Wen Lo
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

5.  A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions.

Authors:  Cynthia M Estrada-Zuniga; Zi-Ming Cheng; Purushoth Ethiraj; Qianjin Guo; Hector Gonzalez-Cantú; Elaina Adderley; Hector Lopez; Bethany N Landry; Abir Zainal; Neil Aronin; Yanli Ding; Xiaojing Wang; Ricardo C T Aguiar; Patricia L M Dahia
Journal:  Cell Rep Med       Date:  2022-07-19

6.  Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.

Authors:  Marialuisa Moccia; Donglin Yang; Naga Rajiv Lakkaniga; Brendan Frett; Nicholas McConnell; Lingtian Zhang; Annalisa Brescia; Giorgia Federico; Lingzhi Zhang; Paolo Salerno; Massimo Santoro; Hong-Yu Li; Francesca Carlomagno
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.